ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0875

Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0817

Predictive Severity Factors of COVID-19 in Patients with Rheumatic Immune Mediated Diseases

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0919

Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0845

Predictors of Moderate-Vigorous Physical Activity Following a Physical Therapist Led Physical Activity Intervention for Adults with Total Knee Replacement

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 1015

Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0952

Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0965

Pregnancy Outcomes in a Diverse Lupus Cohort

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0741

Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0676

Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature

Antiphospholipid Syndrome Poster

9:00AM-10:30AM: Abstract Number: 0760

Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0674

Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies

Antiphospholipid Syndrome Poster

9:00AM-10:30AM: Abstract Number: 0727

Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0991

Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 1089

Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0655

Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

SLE – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].